CD276 and esophageal squamous cell carcinoma: The efficacy of iPSC CD276-targeted CAR-NK cells against CD276-expressing human ESCC was validated in preclinical testing models, demonstrating the feasibility of induced pluripotent stem cell-derived CAR-targeted natural killer cells.